Us Business

Launch of two high value products faces delays and its manufacturing plants are under regulatory scrutiny 

Black Friday crowds thin despite deals

An estimated 166.3 million people are planning to shop from Thanksgiving Day through Cyber Monday this year, according to the National Retail Federation, almost 8 million more than last year

Small-business failures loom as federal aid dries up

Many experts still expect Democratic and Republican leaders to reach a deal on an aid package that includes support for small businesses, but a new, large-scale programme seems increasingly unlikely

Excl: JSW Group scion Parth Jindal on turnaround of US biz

Sajjan Jindal has never stayed away from making big bets. And as his son Parth Jindal completes almost four years in JSW Group, CNBC-TV18 caught up with the heir apparent of the JSW Group in his first-ever television interview.

Wockhardt's Ankleshwar unit gets import alert from USFDA

This will negatively impact the company's US business and lead to a negative sentiment in the markets on Monday.

Expect US business to break-even by year-end: ADF Foods

"We are very optimistic about company's business; things are looking good," Bimal Thakkar, Managing Director of ADF Foods told CNBC-TV18.

Torrent Pharma Q1 net slumps 55% to Rs 292 cr, US biz hurts

The firm had posted a net profit of Rs 650 crore for the same period year ago, Torrent Pharmaceuticals said in a filing to BSE.

Expect 10-15 launches in the US this year: Cipla

Initiatives are underway to normalise operations and the management is committed to making its EBITDA trajectory more sustainable in FY17, says Umang Vora, Global COO, Cipla.

India defends right to issue drug 'compulsory licences'

The Commerce Ministry statement comes weeks after Reuters and media in India quoted the US business advocacy group, US-India Business Council (USIBC), as saying India had given private assurances that it would not grant such "compulsory licences".

India agreed to not issue compulsory drug licenses: US industry

The comments were revealed in a submission last month by the US-India Business Council to the US Trade Representative, which is reviewing global intellectual property laws for an annual report identifying trade barriers to US companies.

Foreign bank card firms fear tough China regulatory regime

Such measures, if implemented, would be a blow to global card payment firms, which have been lobbying for more than a decade to access the world's fastest-growing cards market, projected to become the biggest by 2020.

See acceleration in US biz this quarter onwards: Glenmark

Glenmark Pharma reported a 46.92 percent dip in its consolidated net profit at Rs 114.77 crore for the quarter ended December 31, 2014, mainly due to forex losses and increased expenses. The company had posted a profit after tax and minority interest of Rs 216.23 crore for the corresponding period of the previous fiscal.

India Q2 biz has outperformed; maintain guidance: Glenmark

Glenn Saldanha, chief executive officer, Glenmark says that while the US business has been a drag, India business has been an outperformer for the company.

Sun Pharma Q3 net jumps 74%, ups FY14 sales foreast to 29%

Year-on-year net profit increased to Rs 1,531 crore from Rs 881.3 crore and revenues rose to Rs 4,312 crore from Rs 2,865.5 crore.

Deal pipeline better; will do well in 2014: Tech Mahindra

Vineet Nayyar, Vice Chairman of Tech Mahindra expects Mahindra Engineering Services (MES) merger to play a big role in growth going forward.

See Q2 better than Q1; US biz growth in 25-30% range: Lupin

According to Kamal Sharma, Lupin should perform better in Q2 than Q1 and eyes double digit growth as against virtually no growth in Q1.

Analysts raise Sun Pharma FY14 estimates post Q1 results

Sun Pharma wrote-off Rs 2,517 crore to settle a patent litigation with Pfizer, which resulted in a consolidated Q1 net loss of Rs 1,276 crore. However, adjusted profit jumped 56 percent and revenue was up 32 percent, sending the stock up over 8 percent.

Ranbaxy jumps 30%; street cheers US base business growth

Analysts say the company's 26 percent sequential growth in US business was a big positive, and a stock re-rating was on the cards following the improvement visible in its base business.

Tough for Ranbaxy to revive US biz now: Antique

Pharama analyst, Anmol Ganjoo beleives that acceptence of this felony charges will not only be sentiment negative for Ranbaxy but it will hit their brand name too.

Social gifting: the new buzzword in e-commerce

Last year, the buzzword in e-commerce was Groupon Inc and its myriad of competitors that offered daily online coupons to entice shoppers in a down economy. Now, the latest fashion in retail is social gifting, where people get together on Facebook to buy each other gifts.